Janardan Pandey to HIV Antibodies
This is a "connection" page, showing publications Janardan Pandey has written about HIV Antibodies.
Connection Strength
0.346
-
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018 01; 15(1):e1002493.
Score: 0.144
-
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015 Dec; 182(3):289-301.
Score: 0.123
-
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med. 2022 05; 28(5):1022-1030.
Score: 0.048
-
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015 12 23; 7(319):319ra206.
Score: 0.031